Balanced news tone
News Sentiment
BNTX sentiment intelligence
BioNTech SE news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
77/100 classification confidence.
directly relevant articles
high-authority source matches
-0.0% over one week, +0.6% over four weeks, trend inactive, and near fair-value range.
BioNTech: The Market Is Paying Too Much For An Unproven Pipeline (NASDAQ:BNTX)
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
BioNTech SE Sponsored ADR Actuals & Estimates (NASDAQ:BNTX)
This page on TradingView provides financial actuals and estimates for BioNTech SE (NASDAQ:BNTX). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with av
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 17:10
- Source
- TradingView
Price to sales forward of BioNTech SE – NASDAQ:BNTX
The article provides a financial metric, the "Price to sales forward," for BioNTech SE (NASDAQ: BNTX). It presents a data table with "Period," "Value," "Change," and "Change %" for this metric. The content highlights that the market was closed at the time of viewing, with no trad
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 11:10
- Source
- TradingView
BioNTech (BNTX) director Susanne Schaffert files Form 3 ownership
BioNTech director Susanne Schaffert has filed a Form 3, an initial statement of beneficial ownership, identifying her as a director of BioNTech SE. This filing does not indicate any stock purchases, sales, or other share transactions, establishing a baseline of her holdings. The
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 13:39
- Source
- Stock Titan
BioNTech (BNTX) director Low-Friedrich files Form 3 with no trades
BioNTech director Iris Katharina Low-Friedrich has filed an initial Form 3, indicating her new director status at the company. The filing, however, reports no insider transactions or holdings, meaning there were no purchases, sales, or derivative securities beneficially owned at
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 13:39
- Source
- Stock Titan
Enterprise value to EBIT forward of BioNTech SE Sponsored ADR – BSESOF:22UA
This article displays the "Enterprise value to EBIT forward" for BioNTech SE Sponsored ADR (BSESOF:22UA) on TradingView. It appears to be a stub or data point from a financial platform, showing that the market was closed at the time and no trades were recorded for this metric. Th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 11:39
- Source
- TradingView
Is BioNTech SE (BNTX) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Market source
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jun 2026 07:00
- Source
- Market source
Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth Signals
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Market source
BioNTech (BNTX) sets up USD 1.0B Nasdaq ADS repurchase program
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 08 Jun 2026 07:00
- Source
- Stock Titan
BioNTech Stock Forecast | ASCO Oncology Data Update
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 02 Jun 2026 07:00
- Source
- Capital.com
Experimental BioNTech lung cancer drug shows high responses in early trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 May 2026 07:00
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
$1B BioNTech buyback runs to 2027 as company taps cash reserves
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 07 May 2026 07:00
- Source
- Stock Titan
BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- Seeking Alpha
BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- Market source
BioNTech price receives positive push - Forecast today - 05-05-2026
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 05 May 2026 07:00
- Source
- Economies.com
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains?
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 22 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Analysts Offer Insights on Healthcare Companies: Teleflex (TFX), Cigna (CI) and BioNTech SE (BNTX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Apr 2026 07:00
- Source
- The Globe and Mail
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Mar 2026 07:00
- Source
- Morningstar
BioNTech Stock Cratered 18% as Founders Exit to Launch New Venture
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Mar 2026 07:00
- Source
- TIKR.com
Micron and BioNTech among market cap stock movers on Tuesday
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Mar 2026 07:00
- Source
- Investing.com
COVID-19 pioneers launch new mRNA firm, BioNTech targets 15 cancer trials
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Mar 2026 07:00
- Source
- Stock Titan
Why BioNTech Stock Is Getting Crushed Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Mar 2026 07:00
- Source
- The Motley Fool
BioNTech SE's (NASDAQ:BNTX) Price Is Right But Growth Is Lacking After Shares Rocket 26%
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 Jan 2026 08:00
- Source
- simplywall.st